{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:26:28Z","timestamp":1789255588530,"version":"build-2803163510"},"reference-count":17,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We analyzed cost-effectiveness studies related to hematologic malignancies from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), focusing on studies of innovative therapies. Studies that met inclusion criteria were categorized by 4 cancer types (chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatment agents (interferon-\u03b1, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenalidomide, rituximab alone or in combination, and thalidomide). We examined study characteristics and stratified cost-effectiveness ratios by type of cancer, treatment, funder, and year of study publication. Twenty-nine studies published in the years 1996-2012 (including 44 cost-effectiveness ratios) met inclusion criteria, 22 (76%) of which were industry funded. Most ratios fell below $50\u2009000 per quality-adjusted life-years (QALY) (73%) and $100\u2009000\/QALY (86%). Industry-funded studies (n = 22) reported a lower median ratio ($26\u2009000\/QALY) than others (n = 7; $33\u2009000\/QALY), although the difference was not statistically significant. Published data suggest that innovative treatments for hematologic malignancies may provide reasonable value for money.<\/jats:p>","DOI":"10.1182\/blood-2014-07-592832","type":"journal-article","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T01:53:19Z","timestamp":1423187599000},"page":"1866-1869","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses"],"prefix":"10.1182","volume":"125","author":[{"given":"Cayla J.","family":"Saret","sequence":"first","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[{"name":"Center for Health Solutions, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Center for Health Solutions, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jung","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Neumann","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111818060709400_B1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4274\/Tjh.2013.0108","article-title":"Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.","volume":"30","author":"Haznedaro\u011flu","year":"2013","journal-title":"Turk J Haematol"},{"issue":"22","key":"2019111818060709400_B2","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111818060709400_B3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428194.2012.706287","article-title":"Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.","volume":"54","author":"Bianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111818060709400_B4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/jnci\/djp472","article-title":"When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.","volume":"102","author":"Greenberg","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111818060709400_B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2005.04010.x","article-title":"Growth and quality of the cost-utility literature, 1976-2001.","volume":"8","author":"Neumann","year":"2005","journal-title":"Value Health"},{"issue":"16","key":"2019111818060709400_B6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses.","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"issue":"15","key":"2019111818060709400_B7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-effectiveness in Health and Medicine.","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"issue":"9","key":"2019111818060709400_B8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111818060709400_B9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01526.x","article-title":"The cost-effectiveness of bortezomib in relapsed\/refractory multiple myeloma: Swedish perspective.","volume":"85","author":"Hornberger","year":"2010","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111818060709400_B10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(11)70202-9","article-title":"NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.","volume":"12","author":"Doss","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111818060709400_B11","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.1997.15.7.2673","article-title":"Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.","volume":"15","author":"Liberato","year":"1997","journal-title":"J Clin Oncol"},{"issue":"7543","key":"2019111818060709400_B12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review.","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"issue":"7","key":"2019111818060709400_B13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ejca.2008.11.040","article-title":"Public funding of new cancer drugs: Is NICE getting nastier?","volume":"45","author":"Mason","year":"2009","journal-title":"Eur J Cancer"},{"key":"2019111818060709400_B14","author":"National Institute for Health and Clinical Excellence (NICE)"},{"issue":"2","key":"2019111818060709400_B15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"2019111818060709400_B16","first-page":"7","volume-title":"Basic types of economic evaluation. In: Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"3rd ed"},{"key":"2019111818060709400_B17","first-page":"3","volume-title":"Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In: Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/12\/1866\/1383434\/1866.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/12\/1866\/1383434\/1866.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:06:22Z","timestamp":1574100382000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/12\/1866\/33714\/Value-of-innovation-in-hematologic-malignancies-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,3,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-07-592832","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}